CTIS2023-505672-30-00招募中1 期
A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants with Previously Untreated Unresectable or Metastatic Melanoma - BP43963
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 101
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Histologically confirmed unresectable or metastatic melanoma, per the American Joint Committee on Cancer (AJCC) staging system (unresectable Stage III or Stage IV), 2. Radiologically measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, 3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1, 4. Known v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation status, 5. Adequate cardiovascular, hematological, hepatic and renal function., 6. Participants must have known PD-L1 status
排除标准
- •1. Pregnancy, lactation, or breastfeeding, 2. Participants must not have ocular melanoma, 3. Symptomatic central nervous system (CNS) metastases., 4. Significant cardiovascular/cerebrovascular disease within 6 months prior to randomization, 5. Active or history of autoimmune disease or immune deficiency with some exceptions, 6. Prior systemic anticancer therapy for unresectable or metastatic melanoma
研究者
相似试验
进行中（未招募）
1 期
A Study to evaluate the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced MelanomaMedDRA version: 21.1Level: PTClassification code: 10025671Term: Malignant melanoma stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10025670Term: Malignant melanoma stage III Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10066600Term: Melanoma recurrent Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10025650Term: Malignant melanoma Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10027481Term: Metastatic melanoma Class: 10029104Advanced MelanomaCTIS2023-507389-15-00Genentech Inc.130
招募中
1 期
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal AdenocarcinomaPancreatic ductal adenocarcinomaMedDRA version: 21.1Level: LLTClassification code: 10051971Term: Pancreatic adenocarcinoma Class: 10029104CTIS2022-502404-73-00Genentech Inc.566
进行中（未招募）
1 期
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed with or without Cixutumumab as First-Line Therapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Carcinoma - NDAdvanced nonsquamous non-small cell lung carcinomaMedDRA version: 9.1Level: LLTClassification code 10029522EUCTR2010-024014-60-ITEli Lilly and Company Limited, Indianapolis220
进行中（未招募）
不适用
Study of YM155 plus docetaxel as the first treatment option for patients with Her2 negative metastatic breast cancerEUCTR2009-012439-14-CZAstellas Pharma Global Development, Inc. (APGD)100
进行中（未招募）
1 期
Study of YM155 plus docetaxel as the first treatment option for patients with Her2 negative metastatic breast cancerAdenocarcinoma of the breast that is HER2 negative.MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012439-14-BEAstellas Pharma Global Development, Inc. (APGD)100